Leicestershire Health Community
Medicines Formulary
 
back
8 Malignant disease and immunosuppression
Further information on specific drugs available locally and the pathways used is available from the East Midlands Cancer Network.  This includes drugs reviewed as part of NICE technology appraisals


The East Midlands has adopted the Palliative Adult Network Guidelines(PANG) as the single guideline across the region to conform with the requirement for a single guideline within a cancer network.  These are freely available to healthcare professionals.
08-02-04 Other immunomodulating drugs
For drugs used in cancer please see EM Cancer Network website.

Glatiramer Acetate Copaxone®
Restricted

Specialist Neurology prescribing only
High Cost Drug excluded to tariff (NHSE)
See HSC 2002/004 below for conditions of use
Co-paxone 40mg/ml 3 x weekly supported by NHSE and TAS
Blueteq prior approval required before initiation


Restricted Drug Red View adult BNF  View SPC online
Interferon alfa
Restricted
Specialist prescribing only in Hepatitis B&C
High cost drug excluded to tariff. Commissioned by NHSE in line with NICE TA 75 only
Link  NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
 

Restricted Drug Red View adult BNF  View SPC online
Interferon beta
Restricted

Specialist Neurology prescribing only
Includes Avonex®,Rebif® and Betaferon ®(Interferon beta-1b)
High cost drug excluded to tariff (NHSE)
Blueteq prior approval required before initiation
See HSC 2002/004 below for conditions of use

Link  MHRA Advice: Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
 

Restricted Drug Red View adult BNF  View SPC online
Interferon beta-1a Rebif®
Formulary

For Multiple sclerosis in adults in line with NICE TA 527

Blueteq prior approval required before initiation

Implementation Date: September 2018


View adult BNF  View SPC online  HCD
Peginterferon alfa
Restricted
Hepatitis B&C treatment
High cost drug excluded to tariff. Commissioned by NHSE in line with NICE TA75, TA96, TA106, TA200, TA 300, CG165
Link  NICE CG 165: Hepatitis B (chronic): Chronic hepatitis B in children, young people and adults
Link  NICE TA 106: Peginterferon alfa and ribavirin: mild chronic hepatitis C
Link  NICE TA 200: Peginterferon alfa and ribavirin:chronic hepatitis C
Link  NICE TA 300: Peginterferon alfa and ribavirin:chronic hepatitis C in children and young people
Link  NICE TA 75 Interferon alfa (pegylated and non-pegylated) and ribavirin: chronic hepatitis C
 

Restricted Drug Red View adult BNF  View SPC online
Peginterferon beta 1a Plegridy®
Restricted
Specialist Neurology prescribing only
High cost drug excluded to tariff (NHSE)
Two weekly administration
See HSC 2002/004 for conditions of use

Restricted Drug Red View adult BNF  View SPC online
Cladribine Mavenclad®
Restricted

Specialsit neurologist prescribing only. 
For use in line with NICE TA 493
Blueteq prior approval required before initiation
Date decision added to Formulary: March 2018

Link  NICE TA 493: Cladribine tablets for treating relapsing–remitting multiple sclerosis
 

Restricted Drug Red View adult BNF  View SPC online  HCD
Dimethyl Fumarate
Restricted

Supported in line with NICE TA 320 only.
Specialist neurology prescribing
Blueteq prior approval required before initiation

Date decision added to Formulary: November 2014

Link  MHRA Advice: Dimethyl fumarate (Tecfidera): updated advice on risk of progressive multifocal leukoencephalopathy
Link  NICE TA 320: Dimethyl fumarate for Multiple Sclerosis
 

Restricted Drug Red View adult BNF  View SPC online
Teriflunomide  Aubagio®
Restricted
Specialist Neurology prescribing only in line with NICE TA 303
High Cost Drug excluded to tariff (NHSE)
Blueteq prior approval required before initiation

Date of entry of decision to Formulary: April 2014
Link  NICE TA 303:Teriflunomide for treating relapsing–remitting multiple sclerosis
 

Restricted Drug Red View adult BNF  View SPC online
Alemtuzumab
Restricted

Supported by TAS in line with NICE TA 312.

Blueteq prior approval required before initiation

Date decision added to Formulary: August 14

Link  NICE TA 312: Alemtuzumab for Multiple Sclerosis
 

Restricted Drug Red View adult BNF  View SPC online
Daclizumab
Restricted
Supported by TAS in line with NICE TA 441

Blueteq prior approval required before initiation

Date decision added to Formulary: July 17
Link  NICE TA 441: Daclizumab for treating relapsing–remitting multiple sclerosis
 

Restricted Drug Red View adult BNF  View SPC online
Natalizumab  Tysabri®
Restricted
Specialist Neurology prescribing only in line with NICE TA 127.
High cost drug excluded to tariff (NHSE)
Blueteq prior approval required before initiation
Link  MHRA Advice: Natalizumab (Tysabri▼): progressive multifocal leukoencephalopathy - updated advice to support early detection
Link  NICE TA 127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
 

Restricted Drug Red View adult BNF  View SPC online
Fingolimod Gilyena®
Restricted

Specialist Neurology prescribing only in line with NICE TA 254
High cost drug excluded to tariff (NHSE)
Blueteq prior approval required before initiation

Date of entry of decision to Formulary: July 2012

Link  MHRA Advice: Fingolimod (Gilenya▼): risks of progressive multifocal leukoencephalopathy, basal-cell carcinoma, and opportunistic infections
Link  NICE TA 254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
 

Restricted Drug Red View adult BNF  View SPC online
Beta-interferon-1a Avonex®
Restricted

For Multiple sclerosis in adults in line with NICE TA 527

Blueteq prior approval required before initiation

Implementation Date: September 2018 

Link  NICE TA 527: Beta interferons and glatiramer acetate for treating multiple sclerosis
 

Restricted Drug Red View adult BNF  View SPC online
Beta-interferon-1b Betaferon®
Restricted

For Multiple sclerosis in adults in line with NICE TA 527

Blueteq prior approval required before initiation

Implementation Date: September 2018 

Link  NICE TA 527: Beta interferons and glatiramer acetate for treating multiple sclerosis
 

Restricted Drug Red View adult BNF  View SPC online
Beta-interferon-1b Extavia®
Restricted

For Multiple sclerosis in adults in line with NICE TA 527

Blueteq prior approval required before initiation

Implementation Date: September 2018 

Link  NICE TA 527: Beta interferons and glatiramer acetate for treating multiple sclerosis
 

Restricted Drug Red View adult BNF  View SPC online
Glatiramer Acetate Copaxone®
Restricted

For Multiple sclerosis in adults in line with NICE TA 527

Blueteq prior approval required before initiation

Implementation Date: September 2018 

Link  NICE TA 527: Beta interferons and glatiramer acetate for treating multiple sclerosis
 

Restricted Drug Red View adult BNF  View SPC online
Dupilumab Dupixent®
Non Formulary
Not reviewed in Leicestershire

Black View adult BNF  View SPC online  HCD
Ocrelizumab Ocrevus®
Non Formulary
Not reviewed in Leicestershire

Black View adult BNF  View SPC online  HCD